Psoriasis Drug ORKA-001 Hits 63.5% PASI 100, Supports Potential for Annual Dosing
ORKA has more than doubled off its 52-week low of $8.91.
Summary
Oruka Therapeutics announced highly positive Week 16 data from its Phase 2a EVERLAST-A trial for ORKA-001 in moderate-to-severe plaque psoriasis. The drug achieved 63.5% PASI 100 (complete skin clearance) and 83% PASI 90 at Week 16, demonstrating strong efficacy comparable to the highest reported in the field. This specific, strong efficacy data builds upon the general "positive clinical trial progress" for ORKA-001 mentioned in the company's recent 10-K filing, providing concrete, de-risking results. Crucially, updated Phase 1 data supports the potential for once-yearly dosing, which would be a significant competitive differentiator in the crowded psoriasis market, potentially making ORKA-001 a preferred product. Investors will now focus on longer-term EVERLAST-A data expected in the second half of 2026 and the progression of the Phase 2b EVERLAST-B trial, with data anticipated in 2027.
At the time of this announcement, ORKA was trading at $101.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $8.91 to $71.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.